MDGL - MADRIGAL PHARMACEUTICALS, INC.

434.8
8.950   2.058%

Share volume: 265,096
Last Updated: 03-04-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.72%

PREVIOUS CLOSE
CHG
CHG%
$425.85
8.95
0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
21%
Profitability 25%
Dept financing 2%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.19%
1 Month
-6.18%
3 Months
-24.68%
6 Months
0.44%
1 Year
25.20%
2 Year
74.98%
Key data
Stock price
$434.80
P/E Ratio 
0.00
DAY RANGE
$423.98 - $443.60
EPS 
-$12.85
52 WEEK RANGE
$265.00 - $615.00
52 WEEK CHANGE
$32.25
MARKET CAP 
13.226 B
YIELD 
N/A
SHARES OUTSTANDING 
22.940 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-06-2025
BETA 
0.68
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$355,388
AVERAGE 30 VOLUME 
$395,343
Company detail
CEO: Paul A. Friedman
Region: US
Website: madrigalpharma.com
Employees: 90
IPO year: 2007
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Madrigal Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the. treatment of non-alcoholic steatohepatitis.

Recent news